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BACKGROUND. Dietary changes have led to a growing prevalence of Type 2 
diabetes and non-alcoholic fatty liver disease. A hallmark of both disorders is hepatic 
lipid accumulation, derived in part from increased de novo lipogenesis. Despite the 
popularity of high protein diets for weight loss, the effect of dietary protein on de novo 
lipogenesis is poorly studied. We aimed to characterise the effect of dietary protein on 
de novo lipid synthesis. 
METHODS. We use a 3-way crossover interventional study in healthy males to 
determine the effect of high protein feeding on de novo lipogenesis, combined with in 
vitro models to determine the lipogenic effects of specific amino acids. The primary 
outcome was a change in de novo lipogenesis-associated triglycerides in response to 
protein feeding.  
RESULTS. We demonstrate that high protein feeding, rich in glutamate, increases de 
novo lipogenesis-associated triglycerides in plasma (1.5-fold compared to Control; p 
< 0.0001) and liver-derived very low-density lipoprotein particles (1.8 fold; p < 0.0001) 
in samples from human subjects (n = 9 per group). In hepatocytes, we show that 
glutamate derived carbon is incorporated into triglycerides via palmitate. In addition, 
supplementation with glutamate, glutamine and leucine, but not lysine, increases 
triglyceride synthesis and decreases glucose uptake. Glutamate, glutamine and 
leucine increase activation of protein kinase B, suggesting induction of de novo 
lipogenesis is via the insulin signalling cascade.  
CONCLUSION. These findings provide mechanistic insight into how select amino 
acids induce de novo lipogenesis and insulin resistance, suggesting that high protein 
feeding to tackle diabetes and obesity requires greater consideration. 
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Introduction    
Recent rapid changes in diet have coincided with modernisation, urbanisation, 
economic development, and increased population wealth, and have had a profound 
effect on body composition and health status (1). The transition from traditional diets, 
high in cereal and fibre, to ‘Western-style’ diets high in sugars, fat, and animal-derived 
products are thought to be key contributors to the obesity epidemic and increased 
incidences of metabolic syndrome, type 2 diabetes (T2DM) and non-alcoholic fatty 
liver disease (NAFLD) (2). 
Both NAFLD and T2DM (3) have been associated with increased hepatic lipid 
production via de novo lipogenesis (DNL). This pathway synthesises “new” fat, utilising 
acetyl-coenzyme A (CoA) as a carbon source, derived from a number of metabolic 
reactions including glycolysis or the deamination of amino acids. Fatty-acyl chains can 
then be incorporated into a variety of lipid species, including triacylglycerols (TAG) and 
phospholipids. The pathway commences by carboxylation of acetyl-CoA to malonyl-
CoA by acetyl-CoA carboxylase (ACC). Malonyl-CoA is then transferred to a complex 
multifunctional enzyme, fatty acid synthase (FAS). Multiple rounds of activation of 
acetyl-CoA to malonyl-CoA, transferral to FAS and addition to the lengthening carbon 
chain generate palmitate (4). 
DNL is regulated at a transcriptional level by both glucose and insulin. It has previously 
been established that hyperinsulinaemia and high carbohydrate diets “prime” DNL by 
providing a large substrate pool (5, 6). Glucose also stimulates the expression of 
anabolic DNL genes, including those encoding ATP-citrate lyase (ACL), ACC and FAS 
(ACLY, ACACA and FASN, respectively) by the action of the transcription factor, 
carbohydrate response element binding protein (ChREBP) (7). In turn, insulin 
activates the same genes, via protein kinase B/AKT2 (8), by the action of sterol 
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regulatory binding protein 1c (SREBP-1c), one of two transcripts produced from the 
sterol response element-binding protein gene. Once fatty acids (FAs) are synthesised, 
they are subsequently desaturated via the action of stearoyl-CoA desaturase 1 
(SCD1), and/or elongated, by elongation of very long fatty acids protein 6 (ELOVL6). 
Finally, fatty acids may be incorporated into TAGs and packaged into very low density 
lipoproteins (VLDLs) for export. 
Accumulation of a subset of shorter chain TAGs (scTAGs) and VLDL-associated 
scTAGs in the liver and blood, respectively, has been associated with DNL and hepatic 
steatosis (9). In healthy humans, the amount of de novo-produced TAG incorporated 
in VLDL is small (below 5%; (10)). However, in hyperinsulinaemic individuals with 
NALFD, de novo-produced TAG content increases to 26% (4).  Furthermore, in healthy 
human subjects, feeding with a high carbohydrate meal is sufficient to increase DNL-
derived TAG content to 23% (10). Whilst numerous studies have shown that high 
carbohydrate feeding increases DNL (11), studies of the effect of high protein feeding 
in relation to DNL in humans are limited.  
The branched-chain amino acids (BCAAs), leucine, isoleucine and valine, are known 
to correlate with insulin resistance and T2DM in humans (12). Studies have 
demonstrated that deprivation of BCAAs from the diet whilst maintaining levels of other 
amino acids is sufficient to improve glycaemic control (13). Increased circulating 
BCAAs are sensed by mammalian target of rapamycin (mTOR), a protein kinase which 
is a critical node of the insulin signalling cascade, and subsequently promote DNL 
(14). Hyperactivation of the mTOR pathway by excessive amino acid concentrations 
leads to the phosphorylation of multiple serine residues within, and subsequent 
inactivation of, the insulin receptor substrate 1 (IRS-1) (15). This results in a weakened 
response to insulin, progressing to persistent insulin resistance. Despite this, high 
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protein/low carbohydrate diets are popular regimes for weight loss in humans and 
dietary protein has been shown to decrease hepatic lipid accumulation in rodents (16). 
Presently, the precise amino acid components that are responsible for these effects, 
and the extent to which amino acids are able to induce DNL and VLDL secretion are 
not known.  
The primary objective of this study was to characterise the effect of dietary amino acids 
on DNL. We demonstrate that high protein feeding, using a soy protein intervention 
rich in glutamate, results in increased levels of scTAGs and VLDL-associated scTAGs, 
that have been associated with DNL (9), in plasma of human male subjects. Only 
males were recruited due to the large difference between the lipid profiles of men and 
pre-menopausal women arising from different sex hormones, which are important 
regulators of lipid metabolism (17). We also determine that glutamate induces DNL 
and is itself incorporated in fatty acids via the TCA cycle in hepatocytes, most likely 
via reductive carboxylation. In addition, supplementation with the BCAA leucine and 
glutamine in hepatocytes resulted in a significant increase in scTAGs as well as a 
decrease in glucose uptake. This may provide insight into the negative effects of 
BCAAs on insulin sensitivity and metabolic health, and was recapitulated in both 









Results   
scTAGs are major discriminant variables between high protein- and control-fed healthy 
male subjects 
Nine healthy male subjects completed the trial protocol (Figure 1); baseline 
characteristics for these volunteers are summarised in Table 1. The subjects 
consumed an isoenergetic (2 MJ) control meal (C), high protein meal (HP) and a high 
fat meal (HF), and plasma samples were collected hourly over 6 h. To assess changes 
in the plasma triglyceride profiles obtained by LC-MS, data were processed by 
constructing Principal Components Analysis (PCA) models to identify the distribution 
of the variables and remove any outliers detected using the Hotelling’s T2 test. 
Subsequently, orthogonal projections to latent structures discriminant analysis (OPLS-
DA) models were created to discriminate between the three groups. In the OPLS-DA 
models, time points T3, T4 and T5 were utilised as this provided sufficient time for 
ingested macronutrients to reach the extrahepatic blood (18). OPLS-DA readily 
separated the HP group from the C group (R2X = 0.84, Q2 = 0.47; Figure 2A). However, 
there was a less clear separation between the HP group from the HF group (R2X = 
0.54, Q2 = 0.32; Figure 2B). Both models were validated using permutation tests, 
yielding R2X and Q2 (R2 = (0.0, 0.56), Q2= (0.0, -0.63); R2 = (0.0, 0.21), Q2= (0.0, -
0.30) respectively) lower than the original, hence indicating stable and non-random 
models (Figure 2C & D). Cross validation analysis of variance (CV-ANOVA) also 
showed a significant p-value for both models (p = 0.0063 and p = 0.0032, respectively).  
The loadings plot of the C versus HP model was then used to determine the metabolite 
features that differ between the groups (Figure 2E). Variable importance on projection 
(VIP) was utilised to filter important metabolites in the model. The vectors in the 
projection are regularised such that, if all variables were of equal importance, their 
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values would be equal to 1. Therefore, any variable with a VIP value greater than 1 
was considered to be a potential discriminant variable. TAGs containing shorter and 
more saturated fatty acids (red circles; Figure 2E) were the major VIPs increased in 
the HP group (Figure 2F).   
The TAG profiles were further analysed by hierarchical clustering, and heatmap 
representations were obtained from the Spearman correlation matrix among 
metabolites. One of the clusters contained scTAGs with more saturated fatty acids, 
indicating that changes in TAG levels were consistent within members of the cluster, 
with these scTAGs having been previously correlated with DNL and steatosis, as well 
as cardiovascular disease (19) and risk of developing type 2 diabetes  (20) 
(Supplemental Figure 1).  
 
HP feeding in healthy male subjects increases scTAGs in both plasma and the 
LDL/VLDL fraction. 
The total amount of triglycerides was not significantly different between the three 
groups (Figure 3A). However, total scTAGs were markedly elevated in HP-fed subjects 
3 h post-feeding compared to the same individuals fed with the C or HF meal (Figure 
3B). After an overnight fast and subsequent feeding with the HP meal, there was an 
increase in scTAGs up to 4 h compared with baseline (Figure 3B). There were no 
significant differences in scTAGs between the baseline and hourly samples in C- and 
HF-fed subjects (Figure 3B). To determine whether these TAGs were produced by the 
liver and not the intestine, we extracted LDL/VLDL, through a series of precipitation 
and low-speed centrifugation steps and analysed their TAG profile. In line with 
changes in plasma, the sum of scTAGs in the LDL/VLDL fraction was higher in HP-
fed subjects than C-fed subjects after 3 h (Figure 3C). Fatty acids from the meal as 
well as free fatty acid (FFA) are major precursors of lipoprotein TAGs. The C and HP 
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meals did not have any differences in meal fatty acid compositions (Supplemental 
Table 1) nor in the plasma FFA content (Supplemental Figure 3), suggesting that these 
TAGs were synthesised de novo.  
The plasma 16:0/18:2n-6 ratio was calculated as an index of DNL, since during DNL 
plasma TAGs are enriched with 16:0, the primary product of FAS, and depleted in 
18:2n-6, an essential fatty acid (21). At 4 h, where we saw the biggest increase in 
scTAGs, the 16:0/18:2n-6 ratio was significantly greater after a high protein meal than 
after the C meal (Figure 3D).  
Increases in DNL during high protein feeding may be explained by increases in insulin.  
However, the insulin peak at 30 min was not significantly different between C and HP 
(Supplemental Figure 2). 
 
Glutamate acts as a substrate for the synthesis of triacylglycerols via the TCA cycle 
and DNL-derived palmitate in AML 12 hepatocytes. 
Under physiological conditions carbohydrates act as the canonical source of substrate 
for DNL. However, the contribution of amino acids, derived from protein-rich diets, is 
less well understood beyond the context of oncometabolism. To determine whether 
amino acids act as substrates for DNL under conditions of typical carbohydrate supply 
(approximately 5 mmol/L), we supplemented AML 12 hepatocytes with 13C5-labelled 
glutamate, the most abundant amino acid in the HP meal (Supplemental table 2), to 
trace its metabolic fate. The carbon backbone of glutamate may enter the TCA cycle 
via deamination to α-ketoglutarate. Analysis of subsequent TCA cycle intermediates 
using mass spectrometry showed that, compared to unlabelled samples, the levels of 
labelled TCA cycle intermediate citrate [M+2]+ and [M+5]+ (mass of the unlabelled 
compound plus 2 or 5 Da for the labelled carbons) were markedly increased in labelled 
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samples over 24 h (Figure 4). Interestingly, the [M+4]+ citrate generated by the addition 
of unlabelled acetyl-CoA to [M+4]+ oxaloacetate cannot supply [M+2]+ labelled acetyl-
CoA for the synthesis of fatty acids (22). Whilst citrate is chemically symmetrical, the 
enzymes citrate synthase (CS) and ACL are regiospecific, such that the acetyl-CoA 
cleaved by ACL is the same as that added by CS (23, 24). The 13C label from 
glutamate was detected in the [M+4]+ ion of palmitate, which was found to be 
significantly increased in labelled samples 3 h post-supplementation (Figure 5A). Once 
fatty acids are synthesised, they are packaged into TAGs and exported from the liver 
as VLDL. We further detected the label in the scTAG 48:0 both intracellularly and in 
the cell culture media (Figure 5B).  
As such, we suggest the most likely process by which carbon from glutamate was 
incorporated into FAs was via reductive carboxylation in the TCA cycle. This reverse 
flow through the TCA cycle typically occurs during periods of decreased NAD+ to 
NADH ratio, corresponding to high energy balance, which was detected in glutamate-
supplemented samples compared to control (Figure 5C).  
Taken together, these data suggest that not only do amino acids provide carbon for 
use in DNL, the levels of incorporation of amino acid-derived carbon are appreciable 
even in the presence of physiological glucose concentrations. 
 
Select amino acids increase scTAGs in AML 12 hepatocytes  
We next sought to determine whether amino acids increase DNL and chose 
representatives of glucogenic (glutamate and glutamine) and ketogenic (leucine and 
lysine) amino acids. We supplemented AML 12 hepatocytes with increasing 
concentrations of glutamate, glutamine, leucine and lysine. As expected, intracellular 
amino acid levels increased dose dependently in response to the corresponding amino 
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acid increases in media (Figure 6A). Total scTAG levels increased dose-dependently 
in response to glutamate, glutamine and leucine but not lysine concentrations (Figure 
6B), with the greatest effect achieved by supplementation with leucine. Lysine did not 
increase the levels of scTAGs and in separate experiments, label from 13C6-lysine was 
not detected in palmitate or palmitate-containing triglycerides (Supplemental Figure 
4).  
Glutamate increases the expression of DNL genes  
The synthesis of VLDL particles may be separated into 3 main processes: synthesis 
of fatty acids, elongation and desaturation of fatty acids, and packing of fatty acids into 
triacylglycerols and VLDL. Synthesis of fatty acids is initiated by ATP-citrate lyase 
(Acly), responsible for lysing citrate to acetyl-CoA. Acetyl-CoA is then carboxylated to 
malonyl-CoA, via acetyl-CoA carboxylase (Acaca), which is subsequently utilised by a 
multifunctional enzyme, fatty acid synthase (Fasn), to synthesise fatty acids. 
Increasing levels of glutamate elevated the expression of Acly and Fasn dose-
dependently, with a significant increase at 10 mmol/L glutamate after 24 h (Figure 7A). 
However, there were no changes in the expression of Acaca. Once synthesised, 
palmitate may be desaturated and/or elongated to palmitoleate and stearate by 
stearoyl-CoA desaturase 1 (Scd1) and elongation of very long fatty acids protein 6 
(Elovl6), respectively. Glutamate increased the expression of Scd1 (10 mmol/L 
glutamate) and Elovl6 (4 and 10 mmol/L glutamate; Figure 7B). Fatty acids are then 
sequentially esterified to glycerol to form triglycerides, with the terminal step catalysed 
by diacylglycerol O-acyltransferase 2 (Dgat2). The microsomal triglyceride transfer 
protein (Mttp) is then responsible for shuttling triglycerides through membranes such 
that they may associate with apolipoprotein B100 and apolipoprotein C-III (Apoc3). 
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Glutamate at 10 mmol/L increased the expression of Dgat2 and Apoc3 but not Mttp 
(Figure 7C).  
Profile of expression of DNL genes in response to amino acid supplementation 
Glutamine at 2 and 4 mmol/L increased the expression of the fatty acid synthesis 
genes (Acly and Fasn, but not Acaca), processing and packaging genes (Figure 8A). 
However, at 10 mmol/L glutamine, the expression of Fasn and Elovl6 was no longer 
significantly increased. Despite leucine resulting in the greatest increase in scTAGs in 
hepatocytes, it decreased the expression of fatty acid synthesis (except Acaca) and 
processing genes, with significant changes at 10 mmol/L leucine. However, it 
increased the expression of packaging genes dose-dependently (Figure 8B).  Lysine 
did not change the expression of any genes significantly, in agreement with the finding 
that lysine did not affect scTAG content in hepatocytes (Figure 8C).  
 
Glutamate, glutamine and leucine increase phosphorylation of AKT  
Through a partially characterised mechanism, insulin activates the transcription factor 
SREBP1c to induce the expression of genes required for hepatic DNL. A key node in 
this signalling cascade is PKB/AKT2, a protein kinase that transduces the signal to 
downstream effectors, such as mTOR complex 1 (mTORC1). It is known that amino 
acids activate mTORC1, however, it has only recently been reported that mTORC1 
activation in the absence of PKB/AKT2 is not sufficient to stimulate SREBP1c and thus 
DNL (25). We therefore investigated whether amino acids can act upstream of 
mTORC1 and activate PKB/AKT2 by quantifying the levels of the active kinase, as a 
ratio to total PKB/AKT2, via measuring phosphorylation at Ser 473. In AML12 
hepatocytes, intracellular pPKB/AKT2 levels increased dose-dependently in response 
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to glutamate (4 and 10 mmol/L), glutamine (10 mmol/L) and leucine (4 and 10 mmol/L) 
but not lysine concentrations (Figure 9).  
 
Glutamine and leucine decrease glucose uptake in AML12 hepatocytes 
As insulin resistance is thought, at least in part, to result from the hyperactivation of 
mTOR and the subsequent phosphorylation of IRS1 (26) , we sought to determine the 
acute effects of amino acid supplementation on the uptake of the glucose analogue, 
2-deoxyglucose. This molecule is recognised by glucose transporters, phosphorylated 
within the cell by glucokinase but cannot be further metabolised and is thus 
sequestered within the cell. Upon addition of 2-deoxyglucose, insulin-stimulated 
uptake was significantly lower in both glutamine- and leucine-supplemented cells 

















The latest nutritional transition from traditional to western-style diets (rich in sugar, fat 
and protein from red meat) has led to a growing prevalence of NAFLD and T2DM (3). 
Hepatic lipid accumulation, in part via upregulated levels of DNL, is mutual to both 
disorders. Whilst it is well established that high carbohydrate feeding increases DNL 
(11), studies of the effect of high protein feeding in relation to DNL in humans, are 
limited. Despite high protein/low carbohydrate diets being popular regimes for weight 
loss in humans to prevent obesity and diabetes, recent studies correlated elevated 
BCAA levels with insulin resistance and T2DM (12). The precise dietary amino acid 
composition that may induce DNL is, as yet, unknown. 
In the present 3-way cross over study, healthy human males consumed three meals 
(C, HP and HF) in a randomised order. Only young healthy males were included in 
this study as pre-menopausal females have more variable lipid profiles due to the 
effects of oestrogen and as we were limited in sample size by cost and time constraints 
we chose to focus on males for this study. As the volunteers are healthy, the effects 
observed are a consequence of the parameters of the study, without the confounding 
factor of disease status or variability in lipid profile. In addition, the meals were 
designed such that all three meals were isocaloric. Consequently, and unavoidably, 
the carbohydrate content of the meals varied, which may be considered to confound 
the results. However, the caloric content was considered the more important 
determining factor in metabolic processes, including DNL, and therefore opted to make 
this parameter a constant 2 MJ.  
Lipidomic changes were detected at hours 3, 4 and 5 postprandially, particularly in the 
TAG class of lipids. Using earlier time points, valid models were not generated, 
possibly due to the delay between intake of the meal and its subsequent effect on the 
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blood lipidome. Based on the initial multivariate analysis, we opted to focus on a more 
detailed analysis in the C and HP groups.  
We show that dietary amino acids increase scTAGs, that have been previously 
associated with DNL, steatosis (9) and insulin resistance (20). However, it should be 
noted that these scTAGs are not a direct measure of DNL and this should be 
considered as a limitation of the study that DNL was not directly measured using stable 
isotope based approaches. However, we also show that palmitate may readily be 
derived from glutamate via DNL, suggesting that amino acids may provide carbon as 
a substrate for this process under physiological substrate concentrations. We 
determined differential effects of amino acids on scTAGs as well as the expression of 
genes required for synthesis, processing and packaging of fatty acids, likely involving 
the action of AKT2 in hepatocytes. We demonstrated that a HP meal, rich in glutamate, 
increased scTAGs in plasma as well as in the LDL/VLDL fraction in healthy human 
males. These effects were following a 12-hour fast, which typically supresses DNL 
(27), and so may underestimate the physiological consequences of a high protein meal 
in terms of DNL. Thus, these results may therefore have general implications for high-
protein diets and T2DM. Studies have previously demonstrated that a higher 
protein/lower carbohydrate diet downregulates DNL (28, 29), typically in longer-term 
dietary interventions. However, the precise amino acid composition of the high protein 
diet was not determined, and as we show herein, activation of DNL is specific to certain 
amino acid treatments. The precise metabolic parameters and time-frame of these 
effects on DNL remain to be fully elucidated.  
A master regulator of cell growth, mTORC1, is responsible for sensing nutrient signals, 
particularly amino acids (30). The mTORC1 signalling pathway integrates insulin 
signals, through its phosphorylation by PI3-kinase/AKT2 (31). Activation of mTORC1 
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leads to the nuclear localisation of liver X receptor alpha (LXRα), whereupon it 
heterodimerises with the retinoid X receptor (RXR) to induce the expression of 
lipogenic genes as well as SREBP1c (32). mTORC1 also mediates the nuclear 
translocation of SREBP1c, where it induces the transcription of genes required for 
DNL (33). However, it has recently been reported that mTORC1 activation in the 
absence of AKT2 is not sufficient to stimulate SREBP1c, and thus DNL (25), 
suggesting that amino acids regulate an upstream node in the pathway, or act in an, 
as yet, undetermined manner. Our data show that select amino acids, glutamate, 
glutamine and leucine but not lysine, activated AKT2. This may also indicate that 
specific amino acids may regulate mTOR complex 2 (mTORC2), responsible for the 
activation of AKT2 and subsequent induction in the expression of genes required for 
DNL, in support of a signalling pathway proposed by Tato et al (34).  Amino acids, 
branched-chain in particular, have been linked with insulin resistance. The molecular 
basis is the activation p70 S6k by amino acids (35), a downstream kinase of mTORC1. 
This in turn phosphorylates the insulin receptor substrate at multiple serine/threonine 
residues, thereby attenuating glucose uptake. Persistent activation of p70 S6k by 
excessive amino acid concentrations may therefore lead to insulin resistance (26). 
Herein, we now demonstrate that glutamine and leucine decrease glucose uptake, 
whilst lysine does not.  
In support of our finding that specific amino acids activate PKB/AKT2, we also 
demonstrate that the same amino acids increased scTAG content in hepatocytes. 
Leucine resulted in the greatest increase in scTAG content followed by glutamine and 
lastly, glutamate. Both glutamate and glutamine increased the expression of genes 
required for the synthesis, processing as well as packaging of fatty acids. Perhaps 
surprisingly, leucine and the highest concentration of glutamine decreased the 
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expression of genes required for synthesis and processing of fatty acids but increased 
the expression of genes required for packaging. This suggests a possible negative 
feedback mechanism, whereby accumulation of high levels of scTAGs or other 
intermediate species (such as fatty acyl-CoAs) in the liver inhibit the expression of 
these genes, but not the expression of genes required for subsequent processing and 
packaging. Indeed, studies demonstrate that unsaturated fatty acids lower the levels 
of mRNA for SREBP1c by accelerating its degradation (36), whilst longer chain 
polyunsaturated fatty acids are potent inhibitors of ACC (37). Our findings also suggest 
that fatty acid synthesis and processing genes are differentially regulated to packaging 
genes. SREBP1c induces the expression of genes required for the synthesis (Acly, 
Acaca and Fasn) and processing (Scd1 and Elovl6) of fatty acids (38). On the other 
hand, packaging genes (Mttp and Apoc3) have been shown to be regulated by the 
Forkhead box O1 (FoxO1) transcription factor (39). FoxO1 is responsible for the 
expression of the gene encoding functional MTP, a protein responsible for the 
packaging of lipids with nascent apoB (only present in VLDL) in the endoplasmic 
reticulum. The action of MTP upon the growing VLDL particle is a rate limiting step in 
their formation and release into the blood. Elevated levels of MTP increase the 
secretion of VLDL by the liver and correlate with the pathophysiology of insulin 
resistance and T2DM (40). FoxO1 is itself negatively regulated by insulin, which 
causes its phosphorylation and nuclear exclusion (41, 42). In cases of impaired insulin 
regulation, this may result in uncontrollable levels of MTP (40) expression. The 
production of hepatic, but not intestinal apoCIII is also controlled by FoxO1 via the -
498/-403 element in the apoC3 promoter (41, 43). Two separate insulin signalling 
axes, PI3-kinase/PKB/AKT2 and MAPK(erk), may be responsible for this inhibition. 
While there is evidence supporting a role for both axes (44, 45), our data suggest that 
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PI3-kinase/PKB/AKT2 is not involved in this inhibition, as the expression of Mttp and 
apoC3 are increased in the presence of increased PKB/AKT2. This is consistent with 
the work of Au et al that demonstrated that insulin inhibits the transcription of Mttp via 
the MAPK(erk) signalling cascade, but not that of PI-3 kinase (46). In the context of 
insulin resistance and the development of fatty liver via dysregulated rates of DNL, it 
might be considered hepato-protective to increase the rate at which liver-derived 
lipoproteins are exported, at least in the shorter term. However, it is unlikely that 
prolonged hypertriglyceridaemia, brought about by chronic insulin resistance, has 
equally beneficial effects on long-term metabolic health.   
In summary, our data indicate that high protein feeding increases scTAG content in 
post-fast, healthy human male plasma, indicative of hepatic DNL, and in liver-derived 
lipoproteins. We also demonstrate that specific amino acids are responsible for these 
effects in a cell culture system. The human study utilises only 9 male subjects, this 
should be expanded in a larger and more diverse cohort before generalised 
applicability is possible. As dietary trends have shifted towards high carbohydrate/high 
fat consumption, and high-protein diets are popularised as healthier alternatives, the 
data herein suggest that this is a more complex consideration.  Therefore, advocating 
the consumption of protein in the treatment of diabetes and obesity requires a more 
profound understanding of the roles of amino acids in the context of hepatic DNL in 




Materials and methods 
Human intervention protocol  
General design  
The study was divided into recruitment, pre-screening questionnaire and screening 
visit and three separate study days. Nine healthy, non-smoking men took part in a 
randomised, 3-way crossover study. Twenty-four h before each trial day, the diet and 
activity of each participant was monitored. On the trial day, participants attended the 
Medical Research Council - Elsie Widdowson Laboratory (MRC-EWL) for 7 h and 
received one of the three isoenergetic mixed meals in a randomized order. Nine 
subjects were randomised into one block. Randomisation was generated using a 
computerised program that generates random permutations. Volunteers were 
randomised in a 1:1:1 ratio, such that each volunteer consumed all three meals within 
a period of 6 weeks. The isoenergetic meals comprising: control (C; 15% protein, 40% 
Fat, 45% Carbohydrate), high protein (HP; 32% protein, 33% Fat, 35% Carbohydrate) 
and high fat (14% protein, 62% Fat, 24% Carbohydrate).  
 
Screening visit 
Screening measurements and a blood sample were taken during the screening visit. 
Participants were also requested to complete a 24-hour food diary. After an overnight 
12-hour fast, anthropometric measurements were taken (weight, height and blood 
pressure) and a fasting blood sample was taken. The fasting blood sample was taken 
by venepuncture for analysis of full blood count, liver function, glucose, insulin and 
lipid profile, including total cholesterol, HDL, LDL and triglycerides. These 
measurements were used to determine whether participants met the inclusion criteria 
of the study (Table 2). 
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Study day protocol  
Participants arrived in the morning after a 12-hour overnight fast. Participants were 
cannulated via the antecubital vein of one arm and blood samples were collected, 10 
min apart. Participants then consumed, within 15 min of onset of eating, one of the 
isoenergetic meals. Subsequently blood samples were collected over a six-hour 
period. During the six-hour period, food consumption was not allowed, and only water 
was permitted ad libitum after 3 h had elapsed. Blood samples were collected at 12 
time points at various intervals throughout the 6-hour period (T1 - T6) to perform mass 
spectrometry and determine blood lipid changes after a high protein meal. 
 
LDL/VLDL purification  
Purified LDL/VLDL fractions were obtained using a LDL/VLDL Purification kit 
(Ultracentrifugation free; Cell Biolabs, Inc.). To 200 μL of plasma on ice, 10 μL of 
dextran solution and 100 μL of precipitation solution A were added. The samples were 
incubated for 5 min on ice before centrifuging (6000 x g) for 10 min at 4°C. The 
remaining pellet (containing LDL/VLDL) was resuspended in 80 μL of bicarbonate 
solution and centrifuged (6000 x g) for 10 min at 4°C. The supernatant was transferred 
to a new tube and mixed thoroughly with 1 mL of 1X precipitation solution B and 
centrifuged (6000 x g) for 10 min at 4°C. The pellet was resuspended in 40 μL of 5% 
sodium chloride solution, mixed thoroughly with 1 mL of 1X precipitation solution C 
and centrifuged (6000 x g) for 10 min at 4°C. The above step was repeated, and the 
pellet resuspended in 100 μL of sodium chloride solution. To the mixture 16 μL was 
added of dextran removal solution before incubating for 1 h at 4°C and then 
centrifuging (6000 x g) for 10 min at 4°C. The supernatant (containing purified 
LDL/VLDL) was recovered and stored at -80°C. After acquiring the purified mixture of 
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LDL/VLDL fractions, metabolites were extracted from these fractions as described 
below and analysed by LC-MS of the lipid fraction. 
 
Metabolite extractions  
Metabolites were extracted from blood plasma/cells using the modified method of 
Folch and colleagues (47). Briefly, 15 μL of blood plasma or pelleted cells were mixed 
with chloroform/methanol (2:1, 750 μL); including a mixture of internal standards 
labelled with deuterium (TAGs 45:0-d29, 48:0-d31 and 54:0-d35; Qmx Laboratories 
Ltd.). Samples were sonicated for 15 min and water was added (300 μL). Samples 
were then centrifuged at 13,000 x g for 20 min. The organic (upper layer) and aqueous 
phases (lower layer) were separated. The organic samples, containing the lipid 
extracts, were dried under a stream of nitrogen gas whilst the aqueous samples were 
dried in a CentriVap Centrifugal Concentrator with attached cold trap (78100 series, 
Labconco Co.). 
 
LC-MS of the organic fractions  
The organic fraction was reconstituted in 100 μL chloroform/methanol (1:1), and 10 μL 
added to 90 μL IPA/acetonitrile/water (2:1:1). Analysis of the fractions was performed 
using a LTQ Orbitrap Elite Mass Spectrometer (Thermo Scientific). In positive mode, 
5 μL of sample were injected onto a C18 CSH column, 1.7 μM pore size, 2.1 mm x 50 
mm, (Cat # 186005296, Waters) which was held at 55°C in a Dionex Ultimate 3000 
ultra-high performance liquid chromatography system (UHPLC; Thermo Scientific). A 
gradient (flow rate 0.5 mL/min) of mobile phase A (acetonitrile/water 60:40, 10 mmol/L 
ammonium formate) and B (LC–MS-grade acetonitrile/isopropanol 10:90, 10 mmol/L 
ammonium formate) was used. In negative ion mode, 10 μL of the sample were 
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injected and 10 mmol/L ammonium acetate was used as the additive to aid ionisation. 
In both positive and negative ion mode, the gradient began at 40% B, increased to 
43% B at 0.8 min, 50% B at 0.9 min, 54% B at 4.8 min, 70% B at 4.9 min, 81% B at 
5.8 min, spiked at 99% B at 8 min for 0.5 min, and subsequently returned to the starting 
conditions for another 1.5 min to re-equilibrate the column.  The HPLC was coupled 
to an electrospray ionisation (ESI) source before entering the mass spectrometer. The 
data were collected in both positive and negative ion mode with a mass range of 110–
2000 m/z. Default instrument-generated optimisation parameters were used. Tandem 
MS was performed, using normalised collision energy, to fragment intact lipids listed 
in Supplemental Table 3, in order to identify the fatty acyl chains contained within.  
 
Picolinyl ester fatty acid derivatisation of organic fractions for LC-MS  
Picolnyl esters of fatty acids (PEFAs) were produced using a modification to a method 
published previously (48) to measure total fatty acid content. To each dried organic 
extract 200 µL of 10 µmol/L deuterated internal standard mix (containing FAs 13:0, 
15:0, 17:0 and 20:0) were added and dried under nitrogen. Each sample was fully 
resuspended in 200 µL of oxalyl chloride (2 mol/L in dichloromethane, Cat. # 310670, 
Sigma-Aldrich) and incubated at 65 °C in a heating block for 10 min; achieving 
cleavage of fatty acids from complex lipids and activating the carboxylic group. 
Samples were then dried under nitrogen, resuspended in 200 µL dichloromethane 
(Cat. # 270997, Sigma-Aldrich), and dried again. Each dried residue was then 
resuspended in 150 µL of 1% 3-hydroxymethylpyridine (Cat. # P66807, Sigma-Aldrich) 
in acetonitrile and incubated at room temperature for 5 min to produce derivatised fatty 
acids. The dichloromethane resuspension was repeated to ensure unreacted 3-
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hydroxymethylpyridine had evaporated, dried under nitrogen and stored at -80 °C until 
analysis.  
 
Analysis of total fatty acids by triple quadrupole-mass spectrometry  
PEFAs were reconstituted in 100 µL 2:1 methanol:water and sonicated for 15 min. 
Samples were then centrifuged for 15 min at 13,000 x g to pellet any remaining debris. 
A 2 µL injection volume of the resulting solution was analysed on a TSQ Quantiva™ 
Triple Quadrupole mass spectrometer attached to a Vanquish ultra-high performance 
liquid chromatography system (UHPLC; Thermo Scientific). Chromatographic 
separation was achieved on an Acquity UPLC BEH C18 1.7 µm x 2.1 mm x 50 mm 
column (Cat # 186002350, Waters). Mobile phase A was 100% water with 0.1% formic 
acid and mobile phase B was 50:50 acetonitrile:isopropanol (IPA) with 0.1% formic 
acid. The chromatography gradient started at 30% B for 2.33 min, increased to 100% 
B over 1.34 min and decreased to 30% B for 1.23 min (to re-equilibrate the column) at 
a flow rate of 0.735 mL/min. Default instrument-generated optimisation parameters 
were used. Xcalibur Software (Thermo Scientific) was used to identify peaks, process 
mass spectra and normalise data to the closest-eluting internal standard. 
 
Data processing for open-profiling lipidomics 
Samples obtained from human subjects were acquired in two analytical batches with 
the analytical method described above, along with a set of quality controls (QCs, 
obtained by pooling 15 L of all samples). The resulting raw data files were converted 
into mzML format using the tool MSconvert of the Proteowizard software (49, 50), and 
further processed within the R environment (51) with the libraries IPO, XCMS and 
CAMERA (52–54) to perform parameter optimisation based on the QC samples, peak 
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extraction, grouping, retention time correction, and annotation of adducts and 
isotopes. The output from these pre-processing steps was exported as csv file and 
imported into an adapted implementation of the KniMet (55) pipeline for post-
processing. The LOESS batch correction utility was used to normalise for differences 
among the two analytical batches (based on QCs for intra-batch correction, and on all 
samples for inter-batch). Features were filtered firstly based on their presence in the 
QC samples on the two separate batches with the QC-based feature filtering 
functionality (thresholds for missing values and relative standard deviation (RSD)/ 
coefficient of variation (CV)  = 50% and 20%, respectively), while median peak area 
comparison, as previously described by Dunn and co-workers (56), was used on the 
merged dataset. A summary of the CVs for key lipids are presented in supplementary 
table 3. Metabolites were annotated based on accurate mass using a library built from 
the LIPID MAPS mass spectrometry combinatorial expansion package (57). Finally, 
the data matrix to be utilised for multivariate statistical analysis was subjected to 
missing values imputation with the KniMet MVI-KNN tool. 
 
Growth of AML 12 hepatocytes  
Alpha mouse liver 12 (AML 12) cells were purchased from American Type Culture 
Collection (ATCC) and cultured in 1:1 Dulbecco's modified Eagle's medium and Ham's 
F12 medium (Thermo), supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin (100 units/mL and 100 µg/mL, respectively), 1% Insulin-
Transferrin-Selenium (ITS; 10 mg/L, 5.5 mg/L and 6.7 µg/L respectively) and 
dexamethasone (100 µmol/L) at 37°C in 5% CO2. Cells were removed from liquid 
nitrogen, thawed rapidly and initially cultured in a T25 flask (Cat. # 690175, Greiner). 
Medium was changed every two days, and upon reaching confluence, cells were sub-
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cultured in T75 flasks (Cat. # 7340290, VWR) at a ratio of 1:3. Cells were plated at a 
density of 50,000 cells/well in collagen 1-coated 12-well plates (Cat. # 7340295, VWR) 
and grown to confluence in maintenance medium. Cells were then supplemented with 
low glucose (7.60 mmol/L) with unlabelled L-glutamate (4 mmol/L) and dialysed FBS 
(Thermo) for 2 days. After switching medium, cells were serum-starved for 20 h in low 
glucose medium supplemented with unlabelled L-glutamate (4 mmol/L).  
 
AML 12 cell 13C5-15N-L-glutamate labelling procedure   
Cells were supplemented with glucose (7.60 mmol/L, n=3) with unlabelled-L-glutamate 
(4 mmol/L) or glucose (7.60 mmol/L, n=3) with 13C515N-L-glutamate (4 mmol/L, n=3). 
Based on previous experiments, the cells were allowed 3 h such that the 13C5-15N-L-
glutamate could reach an isotopic steady state in the TCA cycle. Cells and media were 
harvested at 0, 3 and 24 h. 
 
Dose response of glutamate, glutamine, leucine and lysine in AML 12 hepatocytes 
Cells were supplemented with low glucose (7.60 mmol/L, n=3) without the specific 
amino acid (0 mmol/L) or with increasing levels of amino acid (2, 4, 10 mmol/L, 
n=3/amino acid).  Cells and media were harvested after 24 h. 
 
Harvesting of AML12 cells for metabolomics  
For cells and media undergoing metabolomic analyses, 900 µL of medium was taken 
from each well and frozen at -80°C. Each well was then washed with 1 mL of 0.9% 
saline and cells were lifted from the plates by adding 0.5 mL trypsin (10X trypsin-
EDTA, Cat. # 25300045, Invitrogen).  Each well was re-washed with 0.5 mL of 0.9% 
sterile-filtered saline and the resulting solution was transferred into a 2 mL 
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microcentrifuge tube and centrifuged at 13,000 x g for 10 min to pellet the cells. The 
supernatant was removed and the pellet was resuspended in 750 µL of a 2:1 
chloroform:methanol solution to prevent enzymatic degradation of metabolites, and 
frozen at -80°C.  
 
Analysis of aqueous metabolites by triple quadrupolar-mass spectrometry  
Metabolites were extracted as described above and aqueous extracts were 
reconstituted in 50 µL of 10 mmol/L ammonium acetate in water before TCA cycle 
intermediates were separated using reversed phase liquid chromatography using a 
Vanquish UHPLC attached to a TSQ Quantiva triple quadrupole mass spectrometer 
(Thermo Scientific). Multiple reaction monitoring was used in conjunction with 
positive/negative ion mode switching utilising the optimised mass transitions. A C18-
PFP column (150 mm x 2.1 mm, 2.0 µm (ACE)) was utilised at a flow rate of 0.5 
mL/min, with a 3.5 µL injection volume.  For chromatography on the UHPLC system, 
mobile phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic 
acid in acetonitrile. The gradient started at 30% B, increased to 90% B at 4.5 min for 
0.5 min and returned to the starting conditions for a further 1.5 min to re-equilibrate 
the column. Mass transitions of each species were as follows (precursor > product):  
D5-L-proline 121.2 > 74.2; D8-L-valine 126.1 > 80.2; D10-L-leucine 142.0 > 96.2; L-
glutamate [M] 148.0 > 84.2; L-glutamate [M+1] 149.0 > 85.2; L-glutamate [M+6] 154.1 
> 89.1; Citrate 191.0 > 111.0; Citrate [M+1] 192.0 > 112.0; Citrate [M+2] 193.0 > 113.0; 
Citrate [M+3] 194.0 > 114.0; Citrate [M+4] 195.0 > 114.0; Citrate [M+5] 196.0 > 115.0; 
Citrate [M+6] 197.0 > 116.0. Collision energies and RF lens voltages were generated 
for each species using the TSQ Quantiva optimisation function. Xcalibur Software 
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(Thermo Scientific) was used to identify peaks, process mass spectra and normalise 
data to the closest-eluting internal standard. 
 
NAD+/NADH assay  
Briefly, cells were lysed using NAD+/NADH extraction buffer and enzymes that 
consumed NADH were removed by filtration through a 10 kDa spin column (Abcam, 
ab93349). NAD+/NADH was measured according to the manufacturer’s protocol 
(Abcam, ab65348).  
 
RNA extraction and purification from AML12 hepatocytes 
Total RNA was extracted and purified from hepatocytes using an RNeasy Mini Kit 
(QIAgen) according to the manufacturer’s specifications. Purified RNA concentration 
was quantified at 260 nm using a NanoDrop 100 (Thermo Fisher Scientific). 
 
 
cDNA production by reverse transcription  
Each purified RNA sample was diluted with RNase-free water to a final concentration 
of 100 ng/μL. Complimentary DNA (cDNA) synthesis and genomic DNA elimination in 
RNA samples was performed using an RT2 First Strand Synthesis kit (QIAgen) 
according to the manufacturer’s specifications. The reactions were stored at -20°C 
prior to real time PCR analysis. 
 
Quantitative-PCR (qPCR) 
The relative abundance of transcripts of interest was measured by qPCR in RT2 SYBR 
Green Mastermix (QIAgen) with a StepOnePlus detection system (Applied 
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Biosystems). The SYBR Green qPCR Mastermix contained HotStart DNA Taq 
Polymerase, PCR Buffer, dNTP mix (dATP, dCTP, dGTP, dTTP) and SYBR Green 
dye.  Before adding cDNA to each well of the 96-well plate, cDNA was diluted in 
RNase-free water to final concentration 8 ng/μL. PCR component mix was prepared 
by mixing 10 μL SYBR Green qPCR Mastermix with 0.6 μL of 10 μmol/L target primers 
(forward and reverse; 6 pmoles/reaction) and 4.4 μL RNase-free water. To each well 
of a 96-well plate, 5 μL cDNA (total amount 40 ng) and 15 μL PCR components mix 
were added.  The plate was centrifuged at 1000 x g for 30 s to ensure that the contents 
were mixed and to remove any bubbles present in the wells. The plate was placed in 
the real-time cycler with the following cycling conditions: 10 min at 95°C for 1 cycle to 
activate HotStart DNA Taq Polymerase; 15 s at 95°C and 1 min at 60°C to perform 
elongation and cooling for 40 cycles. RT2 qPCR Primer Assays for mouse Rn18s, 
Fasn, Acaca, Acly, Elvol6, Scd1, Dgat2, Mttp and Apoc3 were purchased from 
QIAgen. Expression levels were normalised to the endogenous control, Rn18s, using 
the ΔΔCt method and fold changes reported were relative to the control group in the 
dose response (0 mmol/L ‘amino acid’). 
 
Preparation of cell lysates  
Cell pellets were lysed in 100 μL Cell Extraction Buffer (10 mmol/L Tris, 100 mmol/L 
NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 10 mmol/L NaF, 20 mmol/L Na4P2O7, 20 
mmol/L Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% sodium dodecyl sulfate, 0.5% 
deoxycholate, 1 mmol/L phenylmethylsulfonyl fluoride, complete protease inhibitor 
tablet and 1% of each phosphatase cocktail inhibitor 2 and 3) for 30 min, vortexing at 
10-min intervals. The lysate was centrifuged at 13,000 x g for 10 min at 4°C and the 




Cell AKTpS473 and AKT [total] quantification by enzyme-linked immunosorbent assay  
PKB/AKT concentrations were measured using commercial assay kits (Invitrogen). 
The protocol was followed according to the manufacturer’s specifications. The 
background absorbance was subtracted from all data points, including standards, and 
a standard curve was generated. The unknown concentrations were read from the 
standard curve and the concentrations were multiplied by the appropriate dilution 
factor. Values were normalised to protein concentration using a reducing-agent 
compatible bicinchoninic acid protein assay and values of AKT [pS473] were 
normalised to AKT [Total]. 
 
2-Deoxyglucose uptake assay  
2-Deoxyglucose uptake was measured using a commercial assay kit (Abcam, 
ab136955). The protocol was followed according to the manufacturer’s instructions. 
 
Statistics 
To calculate the sample size of the study, a paired t-test between any two comparisons 
with adjusted multiple comparisons was used. Based on 80% study power, and an 
adjusted α value 0.017, 9 subjects were needed for this study.  
The distribution of the lipid species did not deviate significantly from a normal 
distribution (D'Agostino-Pearson omnibus normality test). Multivariate statistical 
analyses were performed in SIMCA-P software, Version 13.0 (Umetrics, Sweden). All 
variables were UV scaled and subjected to Principal Component Analysis (PCA) 
coupled with Hotelling’s T2 test to evaluate the distribution of the observations and 
identify any possible outliers. Subsequently, samples were classified based on the diet 
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and a supervised OPLS-DA model was developed to maximise separation between 
the different classes. The models were validated by a permutation test (n=100) and 
their significance (p≤0.05) was assessed by submitting the scores of the models to a 
CV-ANOVA test. Loadings plots and the Variable Importance in Projection (VIP) were 
acquired for each model to determine which variables drive the separation between 
classes (threshold limit > 1.0). Once metabolites were annotated in KniMet, and 
analysed in SIMCA, the most discriminant variables were TAGs. Fragmentation (as 
described above) was performed to a group of TAGs to confirm their identity 
(Supplemental Spreadsheet).   
These TAGs were subsequently visualised using univariate statistics. The extent to 
which the model fits and predicts the data is supplied by R2X and Q2X, respectively. 
For univariate statistical analyses, data were visualised using GraphPad (GraphPad 
Prism 5.2; GraphPad Software, San Diego, CA, USA). All data are expressed as 
means with the standard error of the mean (SEM). In GraphPad, 1- or 2-way analysis 
of variance (ANOVA) was performed where appropriate to determine significant 
differences between experimental groups. For 1-way ANOVA, Dunnett’s post-hoc 
multiple comparison test was performed, whilst for 2-way ANOVA, Sidak’s post hoc 
multiple comparison test was used. Differences between experimental groups were 
considered to be statistically significant when p≤0.05.  
Spearman correlation among the metabolic features annotated as TAGs deriving from 
open-profiling lipidomics was calculated and visualised within R (51) using the cor 
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Figure legend  
 
 
Figure 1. Study design flowchart. Seventeen males were screened to examine 
whether they meet the inclusion criteria of the study. Six of them did not meet the 
criteria and another two declined to participate. Nine volunteers participated in a 
randomised 3-way-cross over study. The same nine volunteers attended the Medical 
Research Council – Elsie Widdowson Laboratory at three different occasions and 
received one of the three isoenergetic meals (Control, High Protein and High Fat) in a 
randomised order each time. Blood samples were collected at different time points for 
lipid profile and hormonal analysis. The study was ended once all participants 





Figure 2. Multivariate data analysis of C-, HP- and HF- fed healthy human 
subjects. (A) OPLS-DA scores plot discriminating TAG profiles in plasma of C- and 
HP-fed individuals after 3, 4 and 5 h. Each blue circle represents a single C-fed 
individual, whilst red represents HP-fed individuals (R2X = 0.84, Q2 = 0.47). (B) OPLS-
DA scores plot discriminating TAG profiles in plasma of HF-fed and HP-individuals 
after 3, 4 and 5 h. Each green circle represents a single HF-fed individual, whilst red 
represents HP-fed individuals (R2X = 0.54, Q2 = 0.32). (C) Cross validation of the 
model in (A) acquired through 100 permutation tests; y-axis intercepts: R2 = (0.0, 
0.56), Q2= (0.0, -0.63). n = 9/group. (D) Cross validation of model (B) acquired through 
100 permutation tests; y-axis intercepts: R2 = (0.0, 0.21), Q2= (0.0, -0.30). n = 9/group. 
(E) OPLS-DA loadings plot showing the TAG influence on the separation between the 
HP and C groups. TAGs elevated in HP are displayed on the positive side of the 
predictive component, whilst TAGs elevated in C are displayed on the negative. Red 
circles represent scTAGs. (F) Box plots showing the range of saturated scTAGs in C- 
(blue) and HP-fed (red) individuals). Data are presented as mean ± SEM and analysed 
by two-way repeated measures ANOVA with post-hoc Sidak’s multiple comparisons 






Figure 3. scTAGs are increased in plasma and plasma LDL/VLDL fraction after 
a HP meal in healthy human subjects. (A) Fasting (baseline; 0 h) and postprandial 
total TAG abundance in plasma after C (blue), HP (red) and HF (green) meal 
measured by LC-MS in samples drawn over 6 h. (B) Fasting (baseline; 0 h) and 
postprandial sum of scTAG abundance in plasma after C (blue), HP (red) and HF 
(green) meal measured by LC-MS in samples drawn over 6 h. (C) Fasting (baseline; 
0 h) and postprandial LDL/VLDL scTAG abundance in plasma after C (blue)and HP 
(red) meal measured by LC-MS in samples drawn over 6 h. (D) DNL index reflected 
by the ratio of FA 16:0 to FA 18:2 after C (blue) and HP (red) meal at 3 h and 4 h. Data 
are presented as mean ± SEM and analysed by two-way repeated measures ANOVA 
with post-hoc Sidak’s multiple comparisons test (A-C) or paired t-Test (D); a,b,c = 
p≤0.05, n = 9/group. a = comparisons between C and HP; b = comparisons between 




Figure 4. Carbon from 13C5-labelled glutamate is incorporated into the TCA cycle 
in AML 12 hepatocytes. Labelling in glutamate and citrate, detected by LC-MS over 
24 h post-supplementation. Data are presented as mean ± SEM and analysed by two-




Figure 5. Carbon from 13C5-labelled glutamate is incorporated into DNL-derived 
palmitate and triacylglycerols in AML 12 hepatocytes. (A) Labelling derived from 
glutamate in the [M+4]+ ion of the picolynyl-ester of palmitate (FA16:0) generated by 
DNL, detected by LC-MS over 24 h post-supplementation. (B) Labelling derived from 
glutamate in the [M+2]NH4+, [M+4]NH4+ and [M+6]NH4+ ions of glyceryl tripalmitate 
(TAG 48:0) produced from DNL-derived palmitate in both cells and medium, detected 
by LC-MS after 24 h. (C) NAD+/NADH at 0 mmol/L and 4 mmol/L glutamate after 24 
h. Data are presented as mean ± SEM and analysed by two-way ANOVA with post-





Figure 6. Intracellular scTAGs levels increase dose-dependently in response to 
glutamate, glutamine and leucine but not lysine concentrations in AML 12 
hepatocytes. (A) Amino acid levels in cells in response to specific amino acid 
treatment at 0, 2, 4 and 10 mmol/L concentrations measured by LC-MS after 24 h. (B) 
Sum of scTAG content in cells in response to specific amino acid treatment at 0, 2, 4 
and 10 mmol/L concentrations measured by LC-MS after 24 h. Data are presented as 
mean ± SEM and analysed by one-way ANOVA with post-hoc Dunnett’s multiple 





Figure 7. Increasing glutamate concentration increases DNL synthesis, 
processing and VLDL packaging gene expression for fatty acids in AML 12 
hepatocytes. (A) qPCR analysis of expression of DNL synthesis genes Acly, Acaca 
and Fasn after 24 h. (B) qPCR analysis of expression of processing genes Scd1 and 
Elovl6 after 24 h. (C) qPCR analysis of expression of packaging genes Dgat2, Mttp 
and Apoc3 after 24 h. Data are presented as mean ± SEM and analysed by one-way 




Figure 8. The effect of increasing glutamine, leucine and lysine concentrations 
on DNL synthesis, processing and VLDL packaging gene expression in AML 12 
hepatocytes. (A) qPCR analysis of expression of Acly, Acaca, Fasn, Scd1, Elovl6, 
Dgat2, Mttp and Apoc3 in response to 0, 2, 4 and 10 mmol/L glutamine after 24 h. (B) 
qPCR analysis of expression of Acly, Acaca, Fasn, Scd1, Elovl6, Dgat2, Mttp and 
Apoc3 in response to 0, 2, 4 and 10 mmol/L leucine after 24 h. (C) qPCR analysis of 
expression of Acly, Acaca, Fasn, Scd1, Elovl6, Dgat2, Mttp and Apoc3 in response to 
0, 2, 4 and 10 mmol/L lysine after 24 h. Data are presented as mean ± SEM and 
analysed by one-way ANOVA with post-hoc Dunnett’s multiple comparisons test; * = 




Figure 9. Intracellular pAKT levels increase dose-dependently in response to 
glutamate, glutamine and leucine but not lysine concentrations in AML 12 
hepatocytes. Analysis of AKT activation as a function of AKTpS473 levels detected by 
ELISA after 24 h of amino acid supplementation. Data are presented as mean ± SEM 
and analysed by one-way ANOVA with post-hoc Dunnett’s multiple comparisons test; 




Figure 10. 2-deoxyglucose uptake decreases in response to glutamine and 
leucine but not lysine in AML 12 hepatocytes. (A) 2-deoxyglucose uptake assay 
on AML12 cells exposed to 0, 4 and 10 mmol/L glutamine for 24 h. (B) 2-deoxyglucose 
uptake assay on AML12 cells exposed to 0, 4 and 10 mmol/L leucine for 24 h. (C) 2-
deoxyglucose uptake assay on AML12 cells exposed to 0, 4 and 10 mmol/L lysine for 
24 h. Data are presented as mean ± SEM and analysed by two-way ANOVA with post-
hoc Sidak’s multiple comparisons test; a, b = p≤0.05, n = 3/group. a = comparisons 
between ± insulin within same amino acid concentration; b = comparisons between 












Age Years 24.67 4.24 19-29 
Weight Kg 72.44 7.38 65.5-88.7 
Height m 179.03 7.74 167.8-191.5 
BMI kg/m2 22.66 2.58 18.9-27.5 
Systolic BP mmHg 123.33 8.41 100-140 
Diastolic BP mmHg 71.11 8.54 50-85 
Haematology     
White blood cell 
(WBC)count 
109/L 5.03 0.54 3.9-10.2 
Red blood cell (RBC) 
count 
1012/L 5.10 0.31 4.30-5.75 
Haemoglobin (Hb) g/L 146.89 4.70 135-172 
Haematocrit (Hct) L/L 0.45 0.02 0.395-0.505 
Mean cell volume 
(MCV) 
fL 87.40 5.63 80.0-99.0 
Mean cell haemoglobin 
(MCH) 
pg 28.83 2.08 27.0-33.5 
Red cell distribution 
width (RDW) 
% 13.06 0.79 11.0-16.0 
Platelet (PLT) count 109/L 230.44 28.08 150-370 
Platelet Haematocrit 
(PCT) 
L/L 0.20 0.02 0.19-0.29 
Mean Platelet volume 
(MPV) 
fL 8.67 0.87  
Neutrophil count 109/L 2.74 0.58 1.50-7.70 
Lymphocyte count 109/L 1.48 0.34 1.10-4.50 
Monocyte count 109/L 0.35 0.11 0.10-0.90 
Eosinophil count 109/L 0.09 0.04 0.02-0.50 
Basophil count 109/L 0.03 0.02 0.00-0.20 
Lipid profile, insulin 
and glucose 
    
Cholesterol mmol/L 4.16 0.70 < 5 
Triglyceride mmol/L 0.88 0.36 0.3-1.80 
HDL Cholesterol mmol/L 1.39 0.16 > 1 
LDL cholesterol mmol/L 2.37 0.61 < 2.59 
Cholesterol/HDL Ratio  3.02 0.74 < 3.5 
Non HDL Cholesterol mmol/L 2.77 0.74 <2.95 
Insulin pmol/l 36.33 16.66 0-80 
Serum Glucose mmol/L 4.47 0.33 3.9-5.5 
Liver function     
Albumin g/L 42.8 3.14 35-50 
Total Bilirubin umol/L 15.0 4.12 0-20 
Alkaline Phosphatase U/L 65.3 12.82 30-130 
Alanine Transaminase U/L 20.5 5.72 7-40 
Gamma 
Glutamyltransferase 
U/L 16.1 4.22 0-72 
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Table 2. Exclusion criteria of the human study   
Exclusion criteria Inclusion criteria  
Smokers  Non-smoker males 
BMI ≤18.5 and ≥ 27.5kg/m2 BMI 18.5-27.5 
Allergy or intolerance to any component of 
test meals 
No allergy or intolerance to any 
component of the meals 
Known history of cardiovascular disease  No history of cardiovascular disease  
Impaired fasting glucose (fasting glucose ≥ 
6.1 mmol/L) 
Fasting glucose ≤ 6.1 mmol/L 
Cholesterol ≥ 7.7 mmol/L Cholesterol ≤ 7.7 mmol/L 
Triglycerides ≥ 2.3 mmol/L  Triglycerides ≤  2.3 mmol/L 
Weight reduction medicines, anti-
dyslipidemic agents  
No weight reduction medicines or 
anti-dyslipidemic agents 
Chronic, acute or active metabolic 
(including type 1 and type 2 diabetes 
mellitus) and inflammatory condition, 
haematological disorders, or any other 
systemic illness of renal, hepatic or 
gastrointestinal origin 
No chronic, acute or active metabolic 
(including type 1 and type 2 diabetes 
mellitus) and inflammatory condition, 
haematological disorders, or any 
other systemic illness of renal, 
hepatic or gastrointestinal origin 
Acute and chronic conditions affecting 
gastrointestinal motility  
No acute and chronic conditions 
affecting gastrointestinal motility 
Fat maldigestion and malabsorption  No fat maldigestion and 
malabsorption 
The use of medication known to affect 
gastrointestinal motility (such as 
antiemetic, cathartics, antidiarrheal, 
anticholinergic and narcotic medication)  
No use of medication known to affect 
gastrointestinal motility (such as 
antiemetic, cathartics, antidiarrheal, 
anticholinergic and narcotic 
medication)  
History of mental illness No history of mental illness 
History of substance abuse or alcoholism No history of substance abuse or 
alcoholism 
Current self-reported weekly alcohol intake 
exceeding 14 units per week 
Current self-reported weekly alcohol 
intake less than 14 units per week 
 
 
 
 
 
 
